Compare
Onconetix, Inc. vs Rallybio Corp vs Rafael Holdings, Inc. vs Lexaria Bioscience Corp.
| Latest fiscal year | Onconetix, Inc. ONCO | Rallybio Corp RLYB | Rafael Holdings, Inc. RFL | Lexaria Bioscience Corp. LEXX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-07-31 | 2025-08-31 |
| Revenue | $815.4K | $858.0K | $917.0K | $705.9K |
| Revenue growth (YoY) | -67.7% | +34.9% | +44.0% | +52.0% |
| Gross margin | 77.6% | n/a | n/a | 99.6% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$14.03M | -$8.98M | -$30.52M | -$11.90M |
| EPS (Diluted) | -$16.56 | -$1.59 | -$1.04 | -$0.66 |
| Operating cash flow | -$9.68M | -$29.81M | -$18.92M | -$10.45M |
| Free cash flow | n/a | n/a | -$18.93M | -$10.48M |
| Cash & equivalents | n/a | $31.37M | $52.77M | n/a |
| Total assets | $24.93M | $62.26M | $114.11M | $4.18M |
| Total liabilities | $9.16M | $4.30M | $15.74M | $1.57M |
| Shareholders' equity | $15.76M | $57.96M | $98.37M | $2.99M |
| Return on year-end equity | -89.0% | -15.5% | -31.0% | -398.1% |
| Shares outstanding | 1.56M | 5.28M | n/a | 19.56M |
Revenue, most recent five fiscal years
| Fiscal year | Onconetix, Inc. | Rallybio Corp | Rafael Holdings, Inc. | Lexaria Bioscience Corp. |
|---|---|---|---|---|
| Latest | $815.4K Ended 2025-12-31 | $858.0K Ended 2025-12-31 | $917.0K Ended 2025-07-31 | $705.9K Ended 2025-08-31 |
| 1 year earlier | $2.52M Ended 2024-12-31 | $636.0K Ended 2024-12-31 | $637.0K Ended 2024-07-31 | $464.3K Ended 2024-08-31 |
| 2 years earlier | $58.5K Ended 2023-12-31 | n/a | $279.0K Ended 2023-07-31 | $226.2K Ended 2023-08-31 |
| 3 years earlier | n/a | n/a | $410.0K Ended 2022-07-31 | $255.4K Ended 2022-08-31 |
| 4 years earlier | n/a | n/a | $802.0K Ended 2021-07-31 | $722.7K Ended 2021-08-31 |